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The  etiology  of psychiatric  disorders  is  largely  unknown.  A  role  of  environmental  insults
during  early  neurodevelopment  have  been  suggested.  Infections  are  possible  risk  factors
for psychiatric  disorders  especially  Toxoplasma  gondii,  a neurotropic  parasite  with  a  life-
long  residence  in  brain.  This  study  has  investigated  a possible  role  of  toxoplasmosis  in
the  development  of schizophrenia  and  major  depression  disorder  (MDD).  The  inﬂuence  of
other  covariates;  age,  gender  and  family  history  was  also  studied.  A  cross-sectional  study
on a total  of  177  individuals,  where  anti-Toxoplasma  IgG and  IgM  in  sera  of  schizophrenia
(n  = 63) and  MDD  (n = 39)  patients,  all fulﬁlling  DSM-5  diagnostic  criteria,  were  compared  to
healthy  volunteers  (n = 55).  Toxoplasma  positivity  was highest  (31.75%)  among  schizophren-
ics  followed  by MDD (25.64%)  and controls  (14.55%).  IgG  levels  were  signiﬁcantly  higher  in
toxo-positive  schizophrenics  (230.1  ± 22.9)  and  MDD  (220.56  ±  24.8)  compared  to  controls
(9.98  ± 1.78).  Three  patients  only,  all schizophrenic,  have  positive  IgM antibodies.  Age  and
male gender  appear  to have  positive  associations  to toxoplasmosis  and  psychiatric  disorders
while family  history  has no  obvious  additive  role.  This  report  is  one  of  few  linking  Toxo-
plasma  infection  to  MDD  and  adds  to  many  suggesting  a  link between  latent  toxoplasmosis
and  schizophrenia.
©  2015  Saudi  Society  of  Microscopes.  Published  by Elsevier  Ltd.  All  rights  reserved.1. Introduction
Schizophrenia is a common neuropsychiatric disease
of unsure etiology affecting 1% of the world’s population.
Most of them experience a lifetime disability and about
10% will eventually commit suicide [1]. It overtly mani-
fests in adolescence and early adulthood, but impairments
in neuro-integrative function could be encountered earlier
[2]. Depression is the most common psychiatric disorder in
∗ Corresponding author. Tel.: +966 569722590.
E-mail address: mohaﬁﬁ36@yahoo.com (M.A. Aﬁﬁ).
http://dx.doi.org/10.1016/j.jmau.2015.03.006
2213-879X/© 2015 Saudi Society of Microscopes. Published by Elsevier Ltd. All riman  with approximately 4% of men  and 8% of women are
affected [3]. It presents with depressed mood for at least
2 weeks, along with other symptoms that could include
sleep and appetite disturbances, decreased energy, suicidal
ideation and intention or plan [4].
Little is known about the etiology of schizophrenia and
MDD, but a role of early environmental insults during cru-
cial stages of neurodevelopment, has been suggested. The
neurodevelopmental hypothesis of schizophrenia has been
one of the most acceptable theoretical description of its eti-
ology [5]. Pre- and perinatal infections are largely consid-
ered as risk factors for occurrence of psychiatric disorders
[6,7]. Animal studies demonstrate that perinatal infections
ghts reserved.
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an result in an offspring with neurological and behav-
oral malfunction similar to those of schizophrenia [8,9].
uman studies have offered undeniable evidence that the
isk of schizophrenia is increased by early-life environmen-
al insults, including prenatal infection, and/or immune
timulation [10]. A proof for an inﬂammatory background
f depression has been demonstrated, where T-cells,
onocytes, proinﬂammatory cytokines, oxidative and
itrosative stress are key pathophysiological factors [11].
Among many pathogens linked to psychiatric disorders
12,13], most of the attention is centered on Toxoplasma
ondii,  a neurotropic parasite that has a life-long latent
hase after a usually short and asymptomatic acute stage in
mmunocompetent individuals [14]. The parasite is never
leared from the nervous system where cell-mediated
mmune response mediates its long-life existence [15].
his obligatory intracellular parasite affects one-third of
he world’s population [16], and produces a wide range
f clinical syndromes with an exceptional severity in
mmunocompromised patients [17]. Early trans-placental
nfection might result in a fetal multi-system affection that
ncludes serious CNS abnormalities [18].
The conventional view, that latent toxoplasmosis is usu-
lly asymptomatic and has no long-term sequelae, has
een questioned [19]. There is a compelling evidence that
oxoplasma infection manipulates behavior of many inter-
ediate hosts [20]. Infection with T. gondii altered behavior
f animal models [21] and manipulated the patterns of
any neurotransmitters that mediate the development of
chizophrenia [22]. Recently, a growing number of inves-
igators have linked T. gondii infection to the emergence of
chizophrenia [23–27], however, scarce reports have been
eported about the relation of MDD  and toxoplasmosis
28,29].
Given the known afﬁnity of T. gondii to neural tissues
nd its ability to congenitally induce brain dysfunction,
nvestigating a potential link between Toxoplasma infec-
ion and the pathogenesis of psychiatric disorders, is a
ogic approach. Establishing this link might lead to novel
reventive and therapeutic arrays. The aim of the cur-
ent study was  to explore a possible role of Toxoplasma
nfection in the development of two common psychiatric
iseases, schizophrenia and MDD. Other factors, genetic
nd environmental, that might inﬂuence this association
ere cautiously explored through demonstration of the
ole of age, gender and relevant family history.
. Materials and methods
.1. Study population
A cross-sectional survey was designed to investigate
orrelates of psychiatric disorders in the Mecca Region,
audi Arabia. A probability sample of 280 individuals
aged ≥15 years), all fulﬁlling the diagnostic criteria “The
iagnostic and Statistical Manual of Mental Disorders,
ifth Edition (DSM-5)” [30], were selected from psychiatric
utpatient clinics. All individuals were living within the
ain three cities, Jeddah, Mecca and Taif, of Mecca Region.
 considerable number (178) of patients were excluded
ecause they did not meet the inclusion paradigms for and Ultrastructure 3 (2015) 148–153 149
the study. The rejection criteria were: (1) absence of the
complete data set of the patient in a designed Psychological
Evaluation Report, (2) presence of current or past history
of substance abuse, (3) presence of mental deﬁciencies
or a signiﬁcant neurological disease that would inﬂuence
cognitive functions including mental retardation, epilepsy,
a previous record of head trauma and/or encephalitis. A
total of 55 healthy volunteers were selected as apparently
healthy individuals of the same age and gender with no
history of substance abuse and without documented or
suggestive personal or family history of psychiatric disor-
ders. All participants provided written, informed consent.
2.2. Participants sub-grouping
2.2.1. Measures
Participants were categorized in the following manner:
(1) seropositivity: participants were dichotomized, accord-
ing to anti-Toxoplasma IgG values, as seronegative where
IgG level is <35 International Units (IU)/ml and as seropos-
itive for those with IgG values ≥35 IU/ml; (2) serointensity:
IgG titer levels were log-transformed to reduce positive
skewness, for use as a continuous variable; (3) disease cat-
egory: participants were identiﬁed as either schizophrenic
(n = 63) or having major depressive disease (MDD) (n = 39)
according to clinical examination and data retrieved from a
psychological evaluation report designed to include DSM-5
criteria.
2.2.2. Covariates
The patient study group (n = 102) was  subdivided into
several subgroups according to different covariates; age in
years was self-reported and was  categorized as (1) 15–25
(n = 18), (2) 26–35 (n = 44), or (3) greater than 35 (n = 40).
Gender was dichotomized as female (n = 29) and male
(n = 73) and relevant family history was dichotomized as
positive (n = 28) and negative (n = 74).
2.3. Laboratory analyses
Blood samples (3–5 ml  volume) were collected from all
patients and control subjects after a written informed con-
sent. Sera were separated then delivered on dry ice, in a
real time manner, to our laboratory where samples were
subjected to further processing.
Sera of all participants were analyzed for speciﬁc anti-
toxoplasma IgG and IgM using commercially available
ELISA kits (NovaTec Immundiagnostics GmbH, Dietzen-
bach, Germany), following the manufacturer’s instructions.
Absorbance was read on ELISA microwell plate reader
(Awareness Technology Inc., model 3200, USA) equipped
for the measurement of absorbance at 450 nm/620 nm.
Absorbance values were converted to IgG concentration
(IU/ml) according to a standard calibration curve. IgG
levels ≥35 IU/ml were considered positive. Absorbance val-
ues of the IgM assay were expressed as Nova Tec Units
(NTU) by calculation following the formula, absorbance
value × 10/cut-off. IgM levels ≥11 NTU/ml were considered
positive.
roscopy and Ultrastructure 3 (2015) 148–153
Table 1
Toxoplasma positivity rate and IgG values among different study groups.
Paired groups Toxo positivity
(No./%)
IgG level
(IU/ml)
(Avg. ± SD)
P-value*
Schizophrenia (n = 63)
and
Control (n = 55)
20 (31.57)
8 (14.55)
230.1 ± 22.9
9.98 ± 1.78
0.001
MDD  (n = 39)
and
Control (n = 55)
10 (25.64)
8 (14.55)
220.56 ± 24.8
9.98 ± 1.78
0.001
Schizophrenia (n = 63)
and
20 (31.57) 230.1 ± 22.9 0.234150 N.H. Al-Hussainy et al. / Journal of Mic
2.4. Statistical analysis
Statistical testing were performed with SPSS statisti-
cal program: version 15.0. Two-sided t- and chi-square
tests were used to examine bivariate associations between
T. gondii category, psychiatric disorders, and covariates of
interest. Covariates were considered confounders associ-
ated with T. gondii infection and predictive of the outcomes
of interest. Several comparisons were made between the
different test groups in relation to clinical diagnosis, age,
gender and relevant family history. P-value <0.05 was
regarded as signiﬁcant. All test and control values and rela-
tions were illustrated in descriptive tables.
3. Results
The prevalence of latent toxoplasmosis (as revealed
by anti-Toxoplasma IgG positivity) was higher among
schizophrenic patients (31.75%) followed by patients
with MDD  (25.64%) compared to an incidence of 14.55%
only in healthy controls. A marked elevation of speciﬁc
anti-Toxoplasma IgG antibody levels, among toxoplasma-
positive cases in psychiatric groups (schizophrenia and
depression), was observed. These elevated levels were sig-
niﬁcantly higher compared to the corresponding IgG values
in the control group (Table 1).
Toxoplasma positivity rate was lowest in the youngest
age group (14–25 years) representing 12.5% only of
the schizophrenia group and has no share in the
toxoplasma-positive MDD  cases. The mean IgG val-
ues of schizophrenic as well as MDD  patients of this group,
were statistically insigniﬁcant when compared to control.
Table 2
Toxoplasma positivity rate and IgG values among different age groups.
Paired groups Toxo positivity
(No./%)
Schizophrenia (14–25 years) (n = 8)
and
Control (n = 55)
1 (12.5)
8 (14.55)
MDD  (14–25 years) (n = 10)
and
Control (n = 55)
0 (0.00)
8  (14.55)
Schizophrenia (14–25 years) (n = 8)
and
MDD  (14–25 years) (n = 10)
20 (31.57)
0 (0.00)
Schizophrenia (26–35 years) (n = 25)
and
Control (n = 55)
6 (24)
8 (14.55)
MDD  (26–35 years) (n = 19)
and
Control (n = 55)
6 (31.58)
8 (14.55)
Schizophrenia (26–35 years) (n = 25)
and
MDD  (26–35 years) (n = 19)
6 (24)
6 (31.58)
Schizophrenia (36–50 years) (n = 30)
and
Control (n = 55)
13 (43.33)
8 (14.55)
MDD  (36–50 years) (n = 10)
and
Control (n = 55)
4 (40)
8 (14.55)
Schizophrenia (36–50 years) (n = 30)
and
MDD  (36–50 years) (n = 10)
13 (43.33)
4 (40)
* Signiﬁcant difference if P < 0.05.MDD  (n = 39) 10 (25.64) 220.56 ± 24.8
* Signiﬁcant difference if P < 0.05.
Concerning schizophrenic patients, toxoplasma-positivity
rate was proportional to age reaching 24% and 43.33% in
the middle (26–35 years) and oldest (36–50 years) groups
respectively. Toxoplasma positivity rate was  highest (40%)
among the oldest group of MDD  patients followed by
the middle-aged one (31.58%). Mean IgG values were
signiﬁcantly higher in middle and oldest age groups,
among both schizophrenic and MDD  patients, compared
to their correspondents in the control group (Table 2).
The toxoplasma positivity rate was  lowest in the
youngest age group (14–25 years) representing 12.5%
only of the schizophrenia group and has no share in the
toxoplasma-positive MDD  cases. The mean IgG values of
schizophrenic as well as MDD  patients of this group were
statistically insigniﬁcant when compared to control. Con-
cerning schizophrenic patients, toxoplasma-positivity rate
was  proportional to age reaching 24% and 43.33% in the
IgG level (IU/ml)
(Avg. ± SD)
P-value*
28 ± 14.64
9.98 ± 1.78
0.063
7.81 ± 5.85
9.98 ± 1.78
0.156
28 ± 14.64
7.81 ± 5.85
0.059
76.36 ± 14.73
9.98 ± 1.78
0.001
73.8 ± 19.62
9.98 ± 1.78
0.001
76.36 ± 14.73
73.8 ± 19.62
0.416
71.73 ± 18.31
9.98 ± 1.78
0.001
86.17 ± 26.84
9.98 ± 1.78
0.002
71.73± 18.31
86.17 ± 26.84
0.352
N.H. Al-Hussainy et al. / Journal of Microscopy
Table  3
Toxoplasma positivity rate and IgG values among different gender groups.
Paired groups Toxo positivity
(No./%)
IgG level (IU/ml)
(Avg. ± SD)
P-value*
Schizophrenia (males)
(n = 55)
and
Schizophrenia
(females) (n = 8)
18 (32.37)
2 (25)
185.54 ± 57.24
64.69 ± 26.38
0.004
MDD  (males) (n = 18)
and
6 (33.33) 216.35 ± 69.78 0.001
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(n = 21)
4 (19.05) 49.58 ± 21.94
* Signiﬁcant difference if P < 0.05.
iddle (26–35 years) and oldest (36–50 years) groups
espectively. Toxoplasma positivity rate was highest (40%)
mong the oldest group of MDD  patients followed by the
iddle-aged one (31.58%). Mean IgG values were signiﬁ-
antly higher in middle and oldest age groups, among both
chizophrenic and MDD  patients, compared to their corre-
pondents in the control group (Table 3).
Relevant family history, of a psychiatric disorder, was
tudied as a covariate that might reﬂect both genetic and
nvironmental factors inﬂuencing the association between
oxoplasmosis and schizophrenia and/or MDD. The results
howed that the incidence of toxoplasma positivity, while
igh in all psychiatric groups, was almost evenly dis-
ributed in both family-history positive and family-history
egative groups. The results showed also that the high
nti-Toxoplasma IgG values were evenly distributed in
chizophrenia and MDD  groups regardless of the presence
r absence of a relevant family history with no signiﬁcant
nﬂuence of family history on IgG mean values in both
roups (Table 4).
The prevalence of speciﬁc anti-Toxoplasma IgM anti-
odies was rare. Out of a total of 177 serum specimens
xamined (patients and control), only three patients were
ositive for IgM antibodies. Surprisingly, all three IgM-
ositive cases were belonging to the schizophrenic group
f patients with an incidence rate of 4.76%.
. Discussion
The current study has presented serological evi-
ences that link latent toxoplasmosis with two common
sychiatric disorders, schizophrenia and MDD. The asso-
iation of Toxoplasma infection with psychiatric diseases
as been increasingly acknowledged in the past two
able 4
oxoplasma positivity rate and IgG values in relation to relevant family history.
Paired groups Toxo positiv
(No./%)
Schizophrenia with +ve family history (n = 17)
and
Schizophrenia with −ve family history
(n  = 46)
6 (35.29)
14 (30.43)
MDD  with +ve family history (n = 11)
and
MDD with −ve family history (n = 28)
3 (27.27)
7 (25)
* Signiﬁcant difference if P < 0.05. and Ultrastructure 3 (2015) 148–153 151
decades. Epidemiological as well as serological evidences
have, recently, strengthened the suggestion that Toxoplasm
infection might mediate some psychiatric disorders espe-
cially schizophrenia [26]. Earlier studies indicated that
serologic positivity for toxoplasmosis is almost three times
higher in schizophrenic patients than in healthy individuals
living in the similar geographic area [14,31,32]. T. gondii
seropositivity, in another study, was 2.73 times more com-
mon  in schizophrenic patients than in healthy individuals
[33]. There is also serological evidence that the parasite
may  be involved in the development of Alzheimer’s [34],
Parkinson’s disease [35] and epilepsy of unknown etiology
[36].
Many mechanisms have been suggested to link T.
gondii to psychiatric disorders. Toxoplasma infection,
principally in schizophrenia, represents a main envi-
ronmental trigger mediating the interaction between
personal vulnerability, genetic milieu, neurotransmission
and modulation of the immune system [29]. The neuro-
transmitters link is the most acceptable theory. T. gondii
has a speciﬁc tropism for brain tissue manipulating the
neurotransmitters relevant to some psychiatric disorders
[37,38]. Indoleamine 2,3-dioxygenase, that downregu-
lates serotonin, has been reported to be induced by
toxoplasma infection [29,37]. T. gondii genome contains
genes encoding tyrosine hydroxylase, that upregulates
the synthesis of dopamine [37,39]. The association of
toxoplasmosis with schizophrenia is purportedly due
to dopamine dysregulation and dopaminergic signaling
modiﬁcation by the parasite. Some researchers have
suggested that hyperactive dopaminergic signal trans-
duction may  play a role in the pathophysiology of
schizophrenia [25].
Hypotheses, other than simple infection or neurotrans-
mitter theory, could be proposed to connect toxoplasmosis
and psychiatric disorders. T. gondii has a special afﬁnity
for microglia [18], now thought to be centrally involved in
the schizophrenia pathogenesis [22]. An interesting ﬁnd-
ing states that some drugs, used to treat schizophrenia,
have the ability to hamper the replication of Toxo-
plasma in culture [40]. Another consideration linking
toxoplasma infection to psychiatric disorders is the fact
that Toxoplasma infection induces a host’s immunological
environment with mounting oxidative stress character-
ized by overproduction of toxic free radicals like reactive
oxygen species and nitric oxide [41], involved in the
pathophysiology of many psychiatric and neurodevelop-
mental disorders [10].
ity IgG level (IU/ml)
(Avg. ± SD)
P-value*
81.28 ± 19.68
63.05 ± 18.15
0.078
49.86 ± 12.64
67.63 ± 17.57
0.086
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The current study is one of few studies, tried to explore a
possible link between toxoplasma infection and MDD. On
the contrary of our results, most of these earlier studies
showed no signiﬁcant associations between T. gondii sero-
prevalence and major depression [29,42]. A possible role
of toxoplasma infection in the causation of depression was
suggested in another study [28].
The surprising results of the current study, of low toxo-
plasma positivity rate and insigniﬁcant IgG levels in the
youngest age group, together with almost absence of IgM
prevalence, could suggest an absent role of primary or
reactivated infections in the pathogenesis of schizophre-
nia and/or MDD. Antibody titer is considered as an inverse
correlate of the duration of infection, with the intensity of
personality changes became more evident as the duration
of infection increased [20]. Absence of IgM antibodies in
older study groups, further conﬁrms a prevailing impres-
sion that primary infection was unlikely to be a cause of
schizophrenia [12]. All our results conform to a ﬁnal con-
clusion that latent infection, perhaps going back to the
prenatal era, is the phase of toxoplasmosis that favors the
development of schizophrenia and/or MDD. A broad-scale
detection of IgM in a larger study might help to verify our
ﬁnding.
Relevant family history has no obvious additive role,
according to our results, in predisposing schizophrenia
and MDD. Surprisingly, toxoplasmosis seems to, solely,
orchestrate the pathophysiology of those illnesses. This
ﬁnding contradicts the etiologically heterogeneous nature
of psychiatric disorders that is believed to have a strong
genetic and environmental background [2]. This ﬁnding
could explain why members of the same family that have
a common genetic background and living in the same
environment have different susceptibilities to develop a
psychiatric disorder. It might also suggest that infection
might interact with risk factors, other than genetics, to
precipitate such illnesses.
The “gender factor” had an obvious inﬂuence in our
results where, both the Toxoplasma positivity as well as the
IgG values were signiﬁcantly higher in male patients of all
psychiatric groups. Latent toxoplasmosis impairs the psy-
chomotor performance of human subjects and affects the
human personality proﬁle with an obvious gender differ-
ence [43]. Female sex hormones are known to manipulate
the dopaminergic actions in certain parts of the brain [44]
exerting a protective action on dopamine causing a lower
incidence of degenerative disorders in women such as
parkinsonism [45]. Thus, our ﬁnding could be due to the
protective effect of female sex hormones on dopamine, a
molecule that has long been suggested to be principally
manipulated by T. gondii to induce such disorders [37].
Higher levels of testosterone in males could be responsi-
ble for at least some of the toxoplasmosis-associated shifts
in human and animal behavior [46].
5. ConclusionThe ﬁndings, of the current study, add to a mounting
number of reports suggesting a link between infections,
known to disrupt fetal neurodevelopment, and the risk
of neuropsychiatric disorders especially schizophrenia. In
[
[ and Ultrastructure 3 (2015) 148–153
addition it suggests a possible role of toxoplasmosis in the
development of major depression which is a poorly devel-
oped area with scarce scientiﬁc reports.
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